Imfinzi

Durvalumab, the active ingredient in Imfinzi, is a monoclonal antibody presented as a 500 mg powder for solution for injection for intravenous use. It treats certain advanced cancers, including extensive‑stage small cell lung cancer, unresectable stage III non‑small cell lung cancer after chemoradiation, and selected urothelial, biliary tract and metastatic cancers. It is also indicated for locally advanced or metastatic urothelial carcinoma after platinum‑based chemotherapy, and for biliary tract cancer in combination with chemotherapy. GNH USA supplies Imfinzi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established cold‑chain logistics and regulatory support.

Imfinzi (durvalumab) is a PD‑L1 inhibitor used in several advanced solid‑tumor indications. - Extensive‑stage small cell lung cancer (ES‑SCLC): improves overall survival when given as maintenance therapy after first‑line chemotherapy. - Unresectable stage III non‑small cell lung cancer (NSCLC) after chemoradiation: serves as consolidation therapy to reduce recurrence. - Locally advanced or metastatic urothelial carcinoma after platinum‑based chemotherapy: provides an additional line of treatment to extend disease control. - Biliary tract cancer in combination with chemotherapy: used to enhance response rates in patients with advanced disease.

Imfinzi may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects: - Fatigue: persistent tiredness reported by patients. - Nausea: mild to moderate nausea. - Decreased appetite: reduced food intake. - Skin rash: mild dermatologic reactions.

Serious or Rare Side Effects: - Immune‑mediated pneumonitis: inflammation of lung tissue that can be severe. - Hepatitis: liver inflammation with elevated enzymes. - Endocrine disorders: thyroiditis or adrenal insufficiency requiring hormone replacement.

Before initiating Imfinzi, clinicians should consider several safety measures. - Monitor for immune‑related adverse events: assess organ function regularly. - Evaluate for pre‑existing autoimmune disease: consider risk‑benefit before initiating. - Conduct baseline and periodic imaging: detect pneumonitis early. - Counsel patients on infection signs: report fever or cough promptly. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Imfinzi can interact with other therapies that affect the immune system or organ function.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy and increase risk. - High‑dose corticosteroids: may diminish therapeutic effect. - Organ transplant immunosuppression: increased risk of graft rejection.

Moderate Interactions (Monitor Closely): - Combination chemotherapy: monitor for overlapping toxicities. - Other PD‑1/PD‑L1 inhibitors: avoid sequential use without appropriate washout period.